Krystal Biotech, Inc. · NASDAQ:KRYS
Krystal Biotech — Q2 2025 Earnings Presentation
16 slides from Krystal Biotech's earnings presentation, Aug 4, 2025
Slide 1: Second Quarter 2025 Financial and Operating Results
Second Quarter 2025 Financial and Operating Results August 4, 2025 © Copyright 2025 Krystal Biotech, Inc. All rights reserved.
Slide 2: Forward Looking Statements and Disclosures
Forward Looking Statements and Disclosures This presentation and the accompanying oral presentation contain forward-looking statements that involve substantial risks and uncertainties. Any statements about future expectations, plans, and prospects for Krystal Biotech, Inc. (together with its subsidi
Slide 3: 2Q Earnings Call Topics
2Q Earnings Call Topics ▪ Global VYJUVEK launch ▪ Clinical readouts in lung and eye ▪ Jeune Aesthetics ▪ Sustainable profitable growth Krystal | 3
Slide 4: Over $525M in VYJUVEK Revenue Since Launch
Over $525M in VYJUVEK Revenue Since Launch US$ Millions ▪ Gross margin of 93% in 2Q ▪ Gross to net in 2Q was 17% $91.1 $96.0 ▪ Now over 575 reimbursement approvals $88.2 $83.8 in the U.S. $70.3 $45.3 ▪ U.S. compliance to weekly therapy while $42.1 on drug at 82% as of end of 2Q 2025 $8.6 3Q 4Q 1Q 2Q
Slide 5: VYJUVEK Receives Approval in Japan
VYJUVEK Receives Approval in Japan Broad label provides maximal flexibility to prescribers and patients ✓ Recommended approval for treatment of DEB patients from birth ✓ Also includes option for home administration by either a patient or family member Over 500 ✓ Label mandates a definite diagnosis o
Slide 6: On Track for European Launch Later this Quarter
On Track for European Launch Later this Quarter 3Q Launch 4Q Launch* Germany France Over 575 Over 500 Identified DEB Patients Identified DEB Patients 4 + 38 4 Key DEB Centers Expert DEB Centers * Subject to early access conditions under AP2 program AP2, Accès Précoce 2; DEB, dystrophic epidermolysis
Slide 7: Clear Path to Blockbuster VYJUVEK Franchise
Clear Path to Blockbuster VYJUVEK Franchise ▪ Sales force expansion starting to drive penetration in the U.S. ▪ Europe poised to deliver steady, multi-year growth ▪ Broad label in Japan add another high-value market to VYJUVEK launch ▪ Meaningful opportunities in the rest of the world accessible thr
Slide 8: Pipeline Topics
Pipeline Topics ▪ Deepening and durable responses reported at ASCO in late-line NSCLC treated with KB707 ▪ Confirmed AAT delivery in third patient dosed with KB408 and started repeat dosing ▪ 4 patients enrolled in CF study ▪ Positive KB304 readout in placebo-controlled Phase 1 study ▪ Two new ophth
Slide 9: ASCO 2025 Update Showcases Potential of Inhaled KB707 Monotherapy
ASCO 2025 Update Showcases Potential of Inhaled KB707 Monotherapy ▪ KB707 continued to be safe and generally well tolerated across diverse, heavily pre-treated patient population (n = 39) ▪ Durable monotherapy responses detected in efficacy cohort patients with advanced NSCLC (n = 11)* ▪ All patient
Slide 10: Functional AAT Delivery to the Lungs in Third Patient Dosed with KB408
Functional AAT Delivery to the Lungs in Third Patient Dosed with KB408 Key findings from third Cohort 2 patient with bronchoscopy data; patient was on background IV augmentation 40% High rates of transduction in conducting airways of the lung after single dose of KB408 Reduction in free neutrophil e
Slide 11: Repeat Dosing Now Under Evaluation in KB408 Phase 1 SERPENTINE-1
Repeat Dosing Now Under Evaluation in KB408 Phase 1 SERPENTINE-1 Objectives Key Assessments Evaluate safety and tolerability of repeat dosing at Lung samples will be collected at baseline for all subjects and then for 3 subjects one week after Cohort 2 dose level, as well as assess additive efficacy
Slide 12: Fourth Patient Enrolled in Cohort 3 of KB407 Phase 1 CORAL-1
Fourth Patient Enrolled in Cohort 3 of KB407 Phase 1 CORAL-1 Cohorts 1 and 2 Completed Cohort 1 KB407 109 PFU ✓ No serious adverse events or Single 109 PFU Dose Day 0 Only or dose-limiting toxicities observed Day 0 and Day 1 n=3 ✓ All KB407-related adverse events Cohort 2 Observation mild-to-moderat
Slide 13: Progressing KB304 to Phase 2 Based on Positive Results in PEARL-2
Progressing KB304 to Phase 2 Based on Positive Results in PEARL-2 Décolleté Before and After Images PEARL-2 Study Design • 2:1 randomized, double-blind, placebo-controlled Phase 1 evaluating KB304 for the treatment of wrinkles of the décolleté • Efficacy evaluation included investigator and subject
Slide 14: Second Quarter 2025 Financial Highlights
Second Quarter 2025 Financial Highlights Cash and investments: $820.8 million as of June 30, 2025 Diluted EPS: $1.29 Three Months Ended June 30 Six Months Ended June 30 2025 2024 2025 2024 Product revenue, net $96.0M $70.3M $184.2M $115.5M Cost of goods sold $7.2M $6.0M $12.2M $8.4M Gross margin 93%
Slide 15: Upcoming Readouts
Upcoming Readouts ▪ KB407 Cohort 3 molecular data in CF ▪ Repeat dosing data for KB408 in AATD ▪ Top-line data from KB803 Phase 3 for corneal abrasions in DEB ▪ Top-line data from KB801 Phase 1/2 for NK ▪ KB707 for NSCLC – Readouts to follow AATD, alpha-1 antitrypsin deficiency; CF, cystic fibrosis;
Slide 16: Developing Genetic Medicines to Treat Diseases with High Unmet Medical Needs
Developing Genetic Medicines to Treat Diseases with High Unmet Medical Needs © Copyright 2025 Krystal Biotech, Inc. All rights reserved.